spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  hemophilia B 

 HSMN NewsFeed - 10 Dec 2025
Expression Therapeutics Appoints Industry Veteran Dr. David Townson as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Apr 2024
Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B
Biopharmaceuticals Diagnostics FDA
 HSMN NewsFeed - 22 Nov 2022
U.S. Food and Drug Administration Approves CSL's Hemgenix(R) eEtranacogene dezaparvovec-drlb), the First Gene Therapy for Hemophilia B
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Jul 2020
IDELVION(R) Becomes First and Only Factor IX Therapy with 21-Day Prophylactic Dosing
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Apr 2020
HEMA Biologics(TM) Announces FDA Approval of SEVENFACT(R) [coagulation factor VIIa (recombinant)-jncw] for Treatment and Control of Bleeding Episodes Occurring in Adult and Adolescent Hemophilia A and B Patients with Inhibitors
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Apr 2019
Enzyre Appoints Dirk Pollet as Chief Executive Officer
Diagnostics Personnel
 HSMN NewsFeed - 23 Aug 2018
IDELVION(R) 3500 IU Vials Now Available to Provide Convenience to Patients
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 22 Feb 2018
Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 8 Feb 2018
Novo Nordisk Launches Rebinyn(R) in the United States for People with Hemophilia B
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 26 Oct 2017
FDA Grants Breakthrough Therapy Designation for BioMarin's Valoctocogene Roxaparvovec (formerly BMN 270), an Investigational Gene Therapy for Hemophilia A
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Jun 2017
Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 May 2017
Swedish Orphan Biovitrum AB - Elocta(R) Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Mar 2017
Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-913 Genome Editing Treatment for MPS II
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Feb 2017
Sangamo Therapeutics Announces Chief Financial Officer Succession
Biopharmaceuticals Regenerative Medicine Personnel
 HSMN NewsFeed - 22 Dec 2016
Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study
Biopharmaceuticals
 HSMN NewsFeed - 20 Jun 2016
Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 May 2016
Alprolix(R) (rFIXFc) approved in the EU for the treatment of haemophilia B
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Feb 2016
Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Dec 2015
Syros Pharmaceuticals Appoints David A. Roth, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Dec 2015
Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-FIX, First In Vivo Protein Replacement Platform Program For Treatment Of Hemophilia B
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Nov 2014
Antares Pharma Appoints James E. Fickenscher, Senior Vice President, Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Sep 2014
Dimension Therapeutics Names Annalisa Jenkins as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Aug 2014
Health Canada Approves Eloctate(TM), the First Therapy to Extend the Interval Between Prophylactic Infusions in Hemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Jul 2014
Pfizer Announces Positive Top-Line Results From Phase 3 Study Of NONACOG ALFA (BeneFIX(R)) Once-Weekly Prophylaxis For Hemophilia B
Biopharmaceuticals
 HSMN NewsFeed - 23 Jun 2014
Bayer HealthCare and Dimension Therapeutics to Develop Novel Gene Therapy for Hemophilia A
Biopharmaceuticals
 HSMN NewsFeed - 2 Apr 2014
Baxter to Acquire Chatham Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Mar 2014
Health Canada Approves Biogen Idec's Long-Acting ALPROLIX(TM) Therapy for Hemophilia B
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Dec 2013
Baxter Receives FDA Approval of FEIBA [Anti-Inhibitor Coagulant Complex] for Prophylactic Treatment of Hemophilia A&B Patients with Inhibitors
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Nov 2012
Bayer Announces Recruitment Achievement for Investigational Hemophilia Treatment
Biopharmaceuticals
 HSMN NewsFeed - 20 Nov 2012
Ipsen and Inspiration Biopharmaceuticals Announce That OBI-1 Has Received Fast Track Designation from FDA for Acquired Hemophilia A
Biopharmaceuticals
 HSMN NewsFeed - 2 Nov 2012
uniQure's Glybera(R) First Gene Therapy Approved by European Commission
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 31 Oct 2012
Inspiration Biopharmaceuticals Files for Chapter 11 Protection in Order to Pursue a Broad Strategic Transaction
Biopharmaceuticals
 HSMN NewsFeed - 18 Sep 2012
Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Aug 2012
Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Aug 2012
Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jul 2012
First Gene Therapy in Western World Receives Positive Opinion in Europe from CHMP
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 Apr 2012
Ipsen Pursues Its Development in the United States with the Opening of Its New Commercial Headquarters in New Jersey (NJ)
Biopharmaceuticals
 HSMN NewsFeed - 17 Apr 2012
Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
Biopharmaceuticals
 HSMN NewsFeed - 30 Jan 2012
Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera(R) Marketing Authorisation and Requests Further Information From the CHMP
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 4 Jan 2012
Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Nov 2011
Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Oct 2011
Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jul 2011
Amsterdam Molecular Therapeutics Files Glybera(R) European Marketing Application for Re-examination
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Jun 2011
Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Dec 2010
Swedish Orphan Biovitrum's Long-Lasting Hemophilia A Therapy Receives Orphan Drug Designation in the US
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Dec 2009
AMT Announces Management Changes in Light of Refocused Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Nov 2008
Biovitrum's and Syntonix's Novel Factor IXFc for Hemophilia B has Received Orphan Drug Designation From the FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Jul 2008
Bayer HealthCare and Maxygen Announce Hematology Agreement
Biopharmaceuticals Licensing Acquisitions
 HSMN NewsFeed - 13 May 2008
FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Jan 2008
Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
Biopharmaceuticals
 HSMN NewsFeed - 19 Nov 2007
Cook Pharmica Signs Agreement with Inspiration Biopharmaceuticals for the Transfer of its Clinical Manufacturing Process for Lead Hemophilia Compound
Biopharmaceuticals
 HSMN NewsFeed - 3 Jul 2007
Wyeth Begins Marketing and Distributing BeneFIX in Europe
Biopharmaceuticals Distribution
 HSMN NewsFeed - 26 Mar 2007
Wyeth Receives FDA Approval for New BeneFIX Features That Provide Hemophilia B Patients a Simpler and More Convenient Preparation Process for Recombinant Factor IX
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Mar 2007
Pain Therapeutics Licenses Biotechnology To Treat Rare Disorder
Biopharmaceuticals Licensing
 HSMN NewsFeed - 5 Feb 2007
Wyeth Pharmaceuticals and MediVas Announce Research Partnership to Develop Advanced Hemophilia Therapies
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 5 Feb 2007
Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration to Develop Hemophilia Therapies
Biopharmaceuticals Licensing
 HSMN NewsFeed - 4 Jan 2007
Biogen Idec to Acquire Syntonix
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Nov 2006
Tacere Therapeutics Appoints Vice President, Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jul 2006
Bayer HealthCare Introduces Free Product Trial Program For Kogenate(R) FS with BIO-SET(R)
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 17

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 17 additional stories matching:
hemophilia B
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!